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ABSTRACT
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Introduction
The laboratory rat has been widely used as an animal model in biomedical research. There
are many strains exhibiting a wide variety of phenotypes. Capturing these phenotypes in a
centralized database provides researchers with an easy method for choosing the
appropriate strains for their studies. Current resources such as NBRP and PhysGen provided
some preliminary work in rat phenotype databases. However, there are drawbacks in both
projects: (1) small number of animals (6 rats) used by NBRP; (2) NBRP project is a one-time
effort for each strain; (3) PhysGen web interface only enables queries within a single study –
data comparison and integration not possible; (4) PhysGen lacks a data standardization
process so that the measurement method, experimental condition, and age of rats used are
hidden. Therefore, there is a need for a better data integration and visualization method in
order to provide users with more insights about phenotype differences across rat strains.
The Rat Genome Database (RGD) PhenoMiner tool has provided the first step in this effort
by standardizing and integrating data from individual studies as well as NBRP and PhysGen.
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Methods
Our work involved the following key steps: (1) we developed a meta-analysis pipeline to
automatically integrate data from heterogeneous sources and to produce expected ranges
(standardized phenotype ranges) for different strains, and different phenotypes under
different experimental conditions; (2) we created tools to visualize expected ranges for
individual strains and strain groups; (3) we clustered substrains into different subpopulations according to phenotype correlations.
Results
We developed a meta-analysis pipeline and an interactive web interface that summarizes
and visualizes expected ranges produced from the meta-analysis pipeline. Automation of
the pipeline allows for updates as additional data becomes available. The interactive web
interface provides the researchers with a platform for identifying and validating expected
ranges for a variety of quantitative phenotypes. In addition, we performed a preliminary
cluster analysis that enables researchers to examine similarities of strains, substrains, and
different sex or age groups of strains on a multi-dimensional scale by using multiple
phenotype features.
Conclusion
The data resources and the data mining and visualization tools will promote an
understanding of rat disease models, guide researchers to choose optimal strains for their
research needs, and encourage data sharing from different research hubs. Such resources
also help to promote research reproducibility. Data produced and interactive platforms
created in this project will continue to provide a valuable resource for Translational
Research efforts.
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1. Introduction
1. 1

Model Organisms

Model organisms are important tools in biomedical research. Studies using model organisms
have the potential to reveal the molecular mechanisms underlying disease (1-5) in human.
The large-scale comparative analysis of phenotype and genotype data in model organisms
can further reveal novel associations between genotypes and diseases (6-10). Such analysis
traditionally has not been done as extensively in human.
Rattus norvegicus, or the laboratory rat has been widely used as an animal model for
physiology, immunology, neoplasia, pharmacology, toxicology, nutrition and behavior
research for over 160 years (11). The rat genome sequence project completed in 2004 (12)
has greatly transformed the research paradigm, creating exceptional opportunities for
identifying genes and pathways contributing to disease phenotypes in rats. Results
generated from rat studies can then be translated to human. With the integrated use of
genetic mapping, gene expression and computational analysis, researchers were able to
expand their focus from monogenic rat traits to polygenic traits, including left ventricular
mass (13), heart failure (14), mammary cancer (15), neuroinflammation (16), and
glomerulonephritis (17, 18). A large number of rat strains have been bred to exhibit the
phenotypes of common diseases, either spontaneously, or through the application of
dietary, environmental or other conditions.
In order to leverage the power of the rat for such studies, a clear understanding of the
phenotypic profiles of individual rat strains and commonly used control strains is needed.
Phenotype refers to the observable morphological, physiological and behavioral
characteristics of an individual under certain contexts of a study environment (19). Many
1

phenotypic characteristics can appear or disappear, or increase or decrease in severity
throughout the lifespan of an individual. Phenotypic variation is an expression of genotype,
or the sum of an individual’s genetic makeup and environmental exposure. Thousands of
human diseases are associated with phenotypic and genetic variations. Phenotypes
observed in rats are often similar to those observed for particular human diseases and
researchers will choose particular strains as models of the disease based on these
observations. However, these choices are often based on a single previous experiment, the
researchers’ familiarity with or accessibility of the strain, or the fact that it is commonly seen
by the community as a model for a particular disease. In addition, due to constraints in
resources, individual investigators often focus on a limited number of phenotypes in a given
strain, recording values for these few without recording a comprehensive phenotype profile
of that strain.
Statistical analysis comparing phenotype values between strains is also commonly done in a
single experiment. Unlike physicians in the clinic, rat researchers have not had the benefit of
comprehensive expected (normal or abnormal) ranges for quantitative phenotype
measurements for individual strains or for commonly used control strains based on multiple
studies. The availability of statistically determined quantitative phenotype profiles for a
wide range of rat strains would provide researchers with the data necessary for selecting
optimal strains for their studies and help identify strains with profiles that closely mimic that
of humans with particular diseases. The use of diverse panels of strains, both in phenotype
and genotype, is increasing as a means to represent the diversity of human populations.
Access to comprehensive quantitative phenotype profiles and comparisons with expected
ranges, will facilitate the assembly of such strain panels.

2

1. 2

Current Resources

There have been several attempts to integrate quantitative phenotype data for model
organisms such as mouse and rat to provide researchers with a view of data across
experiments. Current resources include: 1) the Rat Phenome Project of the National
BioResource Project for Rat in Japan (NBRP); 2) the PhysGen and PhysGen knockout
program; 3) the Mouse Phenome Database; 4) the Rat Genome Database PhenoMiner
Project. The Rat Phenome Project by NBRP in Japan, and the PhysGen program and PhysGen
Knockout program are some of the most comprehensive rat phenotype measurement
studies that have been conducted. However, both projects have some limitations (will be
discussed in the following paragraphs). The Mouse Phenome Database is a good example in
terms of data curation and visualization. Their tools provide different visualizations to view
phenotype measurements in one dataset. However, the tools don’t allow comparing or
integrating different phenotype measurements across different studies. The PhenoMiner
project is the forerunner of our current project. It integrates quantitative phenotype records
from multiple experiments using standardized data formats and vocabularies for the sample
used, the phenotype measured, how it was measured and under what experimental
conditions, making it easier to query and compare data from multiple studies. Standardizing
these four components using the Rat Strain Ontology (RSO), Clinical Measurement Ontology
(CMO), Measurement Method Ontology (MMO) and Experimental Condition Ontology (XCO)
was an important step in providing comprehensive phenotype profiles for individual strains
and across strains and to create a foundation on which expected ranges for particular
phenotypes could be determined.
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1)

The Rat Phenome Project by NBRP in Japan

The NBRP Rat Phenome Project in Japan (http://www. anim. med. kyoto-u. ac.
jp/nbr/phenome. aspx) (20) has comprehensively phenotyped more than 250 rat strains on
109 parameters in 7 categories: locomotor activity, neurobehavior, blood pressure, blood
chemistry, hematology, urology, and anatomy. The measurements for each phenotype were
conducted on a group of 6 rats - male or female, aged 5 to 10 weeks, for each strain and
results presented as sample means. For some phenotypes, such as body weight,
measurements were taken at three different time points (5, 6, and 10 weeks) and for others
at a single time point. The NBRP website provides tables which show measurements for a
single strain or tables and bar charts that show measurements across strains for a single
phenotype. They also indicate the research category in which the strain is commonly used (e.
g. diabetes, immunology, cardio-hypertension).
The benefit of using the NBRP Rat Phenome Project methodology is that by constructing
measurement groups with the same number of animals (6 rats), and on both sexes,
researchers could compare the same phenotype across strains (between study variance can
be controlled by using the same number of animals). In addition, conclusions about sex
differences in phenotypes will be easier to draw since the measurements were done under
the same conditions and at the same age.
However, there are some drawbacks to this project: 1) the number of animals (6 rats) they
used was small, resulting in relatively large within study variance; 2) the measurement
method used by NBRP may not be available in other labs. As a result, NBRP phenotype
measurements may be biased and make it hard for researchers to compare their own
results with NBRP measurements; 3) their project is a one-time effort for each strain.
However, even inbred rat strains can drift in their genetic make-up or physiological
4

characteristics. This again makes it hard for researchers to compare their own results with
NBRP measurements. Thus, it is essential to continuously measure rat phenotypes and then
compare or combine old measurement values with new ones.
2)

The PhysGen and PhysGen Knockout Program

The PhysGen (http://pga. mcw. edu/) Program for Genomic Application at the Medical
College of Wisconsin has produced large-scale phenotype data using a variety of inbred,
consomic and knockout rat strains. The PhysGen Program developed two panels of
consomic rats using the SS/JrHsdMcwi, the FHH/EurMcwi and the BN/NHsdMcwi strains (21).
Comprehensive characterization (434, 845 physiological data points) of these consomic
strains, each carrying a chromosome from the sequenced Brown Norway strain, allowed for
immediate mapping of traits to a particular chromosome without the need for genetic
crosses (22). The PhysGen Knockout Program collaborated with several labs to generate
mutant rats through different mutagenesis protocols (23). Inbred, mutant and consomic rat
strains were characterized on 213 mainly cardiovascular phenotypes (24). Utilizing
comparative genomic tools and the available PhysGen rat models, in vivo studies have been
conducted to investigate the role of mutant genes in cardiovascular and metabolic diseases.
The advantage of The PhysGen Program is that it created a federated database with curated
measurements on rats from different laboratories and studies on different rat strains
(inbred, mutant and consomic). The PhysGen Program developed web tools (Figure 1) that
enable querying of experiments for a specific phenotype. The PhysGen website provides
visualization of individual phenotype results across multiple strains with statistical analysis.
It also provides strain profiles which summarize both general and phenotype data for
individual strains (Figure 2) (25).
5

Figure 1 The PhysGen Web Interface for Querying Experiments of a Phenotype (selected “CARDIAC
PROTOCOL”)
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Figure 2 The PhysGen PGA website provides access to strain and phenotype data for more than 70
strains. Users can query by phenotype or strain. Phenotype queries (lower left) return data for all
strains for a single phenotype. Strain profile data for a particular strain across all phenotypes (lower
right) (25)

However, there are several drawbacks to the data as presented: 1) the web interface only
enables queries within a certain protocol or experiment e. g. BIOCHEMISTRY, CARDIAC,
RENAL, RESPIRATORY. However, some phenotypes were measured in multiple protocols. For
example, “heart rate” was measured in both CARDIAC and RENAL which make phenotypebased comparison and integration difficult; 2) it lacks a data standardization process so that
the measurement method, experimental condition and age of rats used remains hidden
7

behind those data points. A user needs to refer to the protocol to gain this information. This
again makes it difficult to truly compare data from various sources and across experiments.
3)

Mouse Phenome Database

The mouse phenome project offers another example of a coordinated effort in phenotyping,
data standardization as well as data federation. In 2001, the Mouse Phenome Project was
launched to complement mouse genome sequencing efforts by promoting new phenotyping
initiatives under standardized conditions and to integrate the data in a central public
database, the Mouse Phenome Database (MPD) (https://phenome. jax. org).
The advantage of MPD is that it has huge collection of mouse research dataset, most of
them contributed from the mouse research community. All phenotype related data were
organized and displayed by dataset (Figure 3). The visualization of each dataset is by default
shown as scatter plot with error bar as mean and standard deviation range (Figure 4). In
addition, it also shows the Measurement Summary, ANOVA, and Q-Q Plot (Figure 5).

Figure 3 Mouse Phenome Database Browse by Phenotype (Systolic Blood Pressure)
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Figure 4 Visualization of Phenotype Measurement in one MPD Dataset
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Figure 5 Visualization of Phenotype Measurement in on MPD Dataset (continued)
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Currently more analysis tools are available for comparing measurement results within study
(Figure 6). Correlation analysis (Figure 7) is available is phenotype measurement was
conducted multiple times with at different time point (or with some other condition
variation criteria). Various ways to compare measurements within a single dataset is also
available (Figure 8). A pivot table (Figure 9) shows the quantitative results in a more concise
manner.

Figure 6 More Analysis Tools in MPD

Figure 7 Scatter Plot and Correlation Analysis
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Figure 8 Side-by-Side (up) and Overlapped (bottom) Comparison

12

Figure 9 Strain Pivot Table

In addition to MPD’s own analysis tool, Figure 10 shows another tool developed by
International Mouse Phenotype Consortium using MPD data (26). Compared to previous
tools that aim to facilitate candidate gene select for GWAS studies, this tool displays an
informative summary chart of gene-phenotype relationships. There are also labels of
phenodeviance, homozygosity/heterozygosity, and sexual dimorphism available. Again,
those labels are assigned by curators and cannot be fully explored or validated by
researchers.

13

Figure 10 “Phenoview”: a Tool that Shows Gene-Phenotype Relationships (26)

However, existing problem with analysis tools provided by MPD is that users can only query
by free text keywords (Figure 11). This might be an obstacle for users not familiar with their
database and ontology to start exploring the database.

Figure 11 Landing Page of MPD for Viewing Phenotype Data

In addition, it only allows users to view records within one study at a time. This limits the
ability to compare and further integrate phenotype measurements across different studies
14

for the same phenotype. MPD have not attempted to integrate phenotype data statistically.
Hence no summary or expected range of phenotype data for a specific strain is available for
reference. This hinders users’ ability to fully explore phenotype differences across mouse
strains. Therefore, there is an urgent need to: 1) develop a more user friendly query
interface for users to browse data in the database (by providing ontologies for query,
showing summaries of data entry counts, etc. ); 2) develop a pipeline or protocol for
evidence-based phenotype assignment utilizing quantitative phenotype data; 3) develop a
tool that supports visualization of integrated quantitative phenotype data in a systematic
manner; 4) increase research reproducibility by enhance data transparency and interactive
data exploration by researchers.
4)

Rat Genome Database and PhenoMiner

The Rat Genome Database (rgd. mcw. edu) is the most comprehensive data repository and
informatics platform for the laboratory rat (27). RGD maintains and updates data about
genes, transcripts, variants and provides functional annotations for disease, pathways,
drug/chemical-gene interactions, gene function and biological processes. In addition to
genomic data, RGD also curates and integrates data on strains, QTLs and experimental
phenotype measurements across hundreds of strains. Data is curated from various sources:
published literature, submitted by individual researchers, and acquired through bulk data
pipelines from other public repositories (27, 28).
As an initial step in developing phenotype profiles for individual strains, RGD created the
PhenoMiner project (29) to integrate quantitative phenotype data from individual research
projects as well as the PhysGen Program for Genomic Application (24), and the NBRP Rat
Phenome Project in Japan (http://www. anim. med. kyoto-u. ac. jp/nbr/phenome. aspx) (20).
15

Each of these large-scale projects were created to present their own quantitative phenotype
data while PhenoMiner was created to integrate data from all of these large scale projects
as well as published results from the literature and data directly submitted from
investigators.

16

RGD uses multiple ontologies to standardize and integrate data from many resources
including the rat strain ontology (RSO) (31), clinical measurement ontology (CMO),
measurement method ontology (MMO) and experimental condition ontology (XCO) (32, 33).
The database structure (Figure 12) includes 11 tables to standardize and link information on
sample measured, type of phenotype measurement and value, measurement method and
the experimental conditions under which the measurement was made. The database
structure provides the ability to record study information, link multiple experiments to a
single study and link multiple phenotype records to a single experiment. The
EXPERIMENT_RECORD table includes information about the quantitative data for a
particular record (value, standard deviation, standard error and measurement units) as well
as the Sample ID, Clinical Measurement Ontology ID, Measurement Method Ontology ID,
and Experimental Conditions Group ID. From EXPERIMENT_RECORD table and links to the
SAMPLE (rat strain, age, sex, number of animals in the experiment),
CLINICAL_MEASUREMENT (Clinical Measurement Ontology table),
MEASUREMENT_METHOD (Measurement Method Ontology Term, measurement site,
apparatuses and measurement duration), CONDITION_GROUP (data on the diet and special
treatment of rats and ordinality and duration of each condition, e. g. “controlled sodium
content drinking water (1 %) (between 9 and 12 days)”, “controlled sodium content diet (0.
3 %) (for 12 days) then controlled sodium content diet (2 %) (for 24 days)”).

17

Figure 12 Database Structure of PhenoMiner

The creation of this structure and the use of multiple ontologies to standardize four
components of a quantitative phenotype record has resulted 60, 000 entries (28). A
summary of quantitative phenotype records in RGD is listed in Table 1.
Table 1 Summary of PhenoMiner Data in RGD

Phenotype Category

Number of Records Number of Strains

alimentary/gastrointestinal measurement

8

5

blood measurement

19491

472

body morphological measurement

10503

777

body movement/balance measurement

98

13

body temperature

349

63

cardiovascular measurement

18334

951

cell measurement

6318

316

chemical response/sensitivity measurement

2285

98

18

consumption measurement

339

19

disease population measurement

426

163

disease process measurement

502

85

endocrine/exocrine system measurement

64

20

exudate measurement

216

4

growth measurement

23

9

immune system measurement

3408

311

liver/biliary measurement

739

236

mortality/survival measurement

52

21

musculoskeletal system measurement

202

14

nervous system measurement

697

242

organ measurement

12037

790

renal/urinary measurement

4883

634

reproduction measurement

62

6

respiratory system measurement

4923

241

tissue composition measurement

139

24

tumor measurement

220

77

19

The advantages of PhenoMiner are: 1) it standardizes quantitative phenotype records for rat
strains, clinical measurements, measurement methods and experimental conditions using
ontologies; 2) this standardization allowed for the integration of data from large scale and
small scale phenotype projects, 3) users can query and retrieve data from multiple
experiments and visualize results, 4) users can also download retrieved data. In this paper
(29), authors demonstrated the use of RGD visualization to compare cardiovascular and
renal phenotypes of SS, SS congenics and SS mutants under salt-induce hypertension model.
In a similar manner, we did a query and the results are display as below (Figure 13).

Figure 13 RGD PhenoMiner Visualization of Individual Records for Query={Strain=”BN”&”WKY”,
Phenotype=”diastolic blood pressure”}

While systematic data integration and visualization in PhenoMiner enabled qualitative
comparisons across experiments and conclusions to be drawn, the drawback of the current
PhenoMiner portal is its limited ability for statistical integration of data. Further quantitative
analysis using a standardized statistical tool would provide more insights in understanding
20

rat strains in terms of disease models. Moreover, an integrated analysis of overall strain
phenotype measurement is desirable for researchers to better understand cross strain
differences. Currently researchers often choose strains for use as disease models using data
points from a limited number of experiments or based on availability, prior use or familiarity.
The availability of statistically determined expected ranges for quantitative phenotypes for
multiple individual strains, for those often used as controls and for rat in general would
improve the ability of investigators to choose appropriate strains for their studies. One
example of the need for statistically determined expected ranges was illustrated with the
commonly used outbred CD-SD rats often seen to be less responsive to estrogenic
substances than F344 inbred rat strains for various estrogen-sensitive endpoints (34, 35).
The authors showed that the commonly held view of the distinct phenotype characteristics
of two strains did not hold true when the results from a collection of experiments were
aggregated. This case illustrates why it would be desirable to have a statistically determined
expected range as a quantitative reference for analyzing measurement data across different
experiments. Such references would help researchers choose better strain models for their
research objective and assist them in examining potential factors that might cause
measurement variation. The expected range would also provide a standard interpretation of
experimental results from different laboratories.

1. 3

Motivation and Aims

Expected ranges for different phenotypes for individual rat strains as well as across multiple
strains are currently not available. Nor is there a tool to help researchers to select an
optimal strain as a disease model. Therefore, the motivation for our work is to take
advantage of the huge volume of quantitative phenotype data in the Rat Genome Database
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to establish expected ranges for different rat strains. By comparing expected ranges for
different rat strains, researchers will be able to choose the optimal disease model and
control for their investigations. To achieve this goal, our work involve the following key
steps: (1) establish a standardized phenotype range for different rat strains using the metaanalysis method, (2) create tools to mine and visualize data for individual strains and across
strains, (3) cluster substrains into different sub-populations according to phenotype
correlations.
In the first step, we conducted a meta-analysis to effectively synthesize archived phenotype
data in the PhenoMiner database, stratify each population based on strain
(inbred/outbred/congenic/transgenic/mutant), gender, age, . and produce comparable
expected ranges of important physiological phenotypes (such as heart weight, systolic blood
pressure). Statistical tests will also be performed to assess differences between different
strains of certain phenotypes. The result from this work will greatly benefit researchers
using rat models in determining a proper strain, age, gender and all relevant parameters for
their studies.
Tools was developed to allow users to search, retrieve and visualize expected ranges for a
variety of phenotypes for a single strain or across strains for a single or multiple phenotypes.
Next, we integrated quantitative expected ranges from the previous steps as essential
phenotype features for rat disease models and use those features to cluster strains into
subtype clusters. The clustering result will provide in-depth insight of the substrain variation
in rats. It can be useful for researchers when they are designing experiments and trying to
pick a substrain suitable for their specific research objective.
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2

Generating Phenotype Expected Ranges

2. 1

Background

A meta-analysis approach is a powerful tool for determining expected ranges for particular
phenotype measurements across multiple experiments. This approach involves statistical
techniques for combining measurements or findings from independent studies to draw
insights on a specific research question. It is often used to assess the effectiveness of clinical
treatments by combining data from several randomized control trials. It provides a precise
estimate of treatment effect, overcoming biases that could occur when examining a single
study and it offers a systematic synthesis of the experimental data. A recent research study
revealed that single-laboratory studies with large sample size produce results that are more
precise but less accurate and therefore less reproducible (36). By contrast, multi-laboratory
designs including as few as 2 to 4 laboratories increased coverage probability by up to 42
percentage points without a need for larger sample sizes. They also demonstrated that
within-study standardization is a major cause of poor reproducibility (36).
A systematic review methodology is essential as the first step of meta-analysis. The
objective of a systematic review is to present a balanced and impartial summary of the
existing research, enabling synthesis of all relevant studies of adequate quality (37). This
stresses the need to take great effort and care to find all the relevant studies (published and
unpublished), and to assess the methodological quality of the design and execution of each
study (38). The standardized and integrated data at RGD is a good resource of systematically
managed experimental phenotype measurements. It includes both data from published
studies from current biomedical literature as well as large scale data from rat community
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repositories such as PhysGen (24), PhysGen Knockout Project (30) and the Rat Phenome
Project (20).
Meta-analysis is not just a single statistical analysis; it involves a pipeline of preliminary
stratification, exploratory decision making (publication bias and sensitivity analysis) before
the final statistical meta-analysis can be performed. The pipeline for analyzing RGD
PhenoMiner data consists of four major components (Figure 14). In the following sections, I
will introduce the methods for each step in the pipeline followed by its corresponding
results since results from each step are useful in deciding the method used in the next step.
In addition to developing the algorithms for each component, a user interface was created
to facilitate determination of appropriate parameters, and to dynamically implement the
workflow needed for the analyses (described in further detail below).

Figure 14 System Pipeline for Meta-Analysis
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2. 2

Preliminary Stratification

First it was necessary to choose a subset of phenotype measurements based on preliminary
stratification, which included strain, sex, age group, and phenotype measurement methods.
Figure 15 show the interface created to dynamically conduct the preliminary stratification
step. Options for strain and phenotype measurement methods depend on the major
phenotype under analysis. Age group divisions were decided by expert heuristic definitions
of young, adult and old rats. However, for different phenotypes, young and adult divisions
can vary in order to achieve a low heterogeneity score. As a result, age group division is a
data-driven heuristic score with expert provided prior definition.

Figure 15 PhenoMiner Preliminary Stratification for Body Weight

2. 3

Publication Bias with Funnel Plot

Because much of the data included in this study arises from published research, one key
concern is publication bias which arises because experiments with negative findings are less
likely to be published than those that highlight results which support hypotheses (39).
Funnel plots can be used to assess the presence of publication bias (40) by displaying the
studies included in the meta-analysis in a plot of measurement value or effect size
(explained in detail in the statistical analysis section) against sample size or another measure
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of precision (41, 42). The expected picture should be a symmetrical inverted funnel (43).
This is in accordance with the assumption that smaller studies have more chance of
variability than larger studies. An asymmetric plot suggests: (1) smaller studies showing no
effect might be missing or (2) small studies tend to have larger effect sizes (44). The first
reveals a true publication bias while the second does not. There are also controversies over
the use of funnel plots due to disputes over appropriate interpretation of asymmetry (4547). For example, true heterogeneity in study population (due to subgroups with a different
intervention effect) will lead to funnel plot asymmetry (47). In addition, chance is also
critical for interpretation of funnel plot asymmetry since most meta-analyses in the
biomedical field contain few studies (48). Therefore we need to examine closely before
reaching a conclusion of publication bias (49).
There are two estimators (Macaskill (50) and Egger (40)) for detecting publication bias. In
our pipeline, we provided two different bias detection methods: funnel plot and funnel
regression test using the Egger estimator.
In 1997, Egger et al. proposed an estimator for visualizing asymmetry in the funnel plot (40).
In addition to the simple visualization of asymmetry, they also used a regression test to
measuring asymmetry quantitatively. The regression test is a linear regression of normalized
effect size estimate (value/SD) against precision(1/SD). The assumption of the regression
test is that a homogeneous set of trials (without publication bias), will regress toward a line
that runs through the origin (intercept = 0), with the slope indicating the size and direction
of effect (51). When the regression line runs through the origin, it indicates a symmetrical
funnel plot. However, the Egger test has a relatively high false positive rate (higher type I
error rate).
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The Macaskill estimator was found to have a lower false-positive rate in simulations (50)
than the Egger estimator, though at the expense of lower power (higher type II error rate).
The Macaskill estimator is similar to the Egger estimator but it used total sample size as a
measure of precision. Use of sample size reduces the correlation between the effect size
and its SD thus avoids violating an assumption of regression models that an independent
variable is subject to random error. A minor modification of Macaskill’s test, with the
inverse of the total sample size as a measure of precision, produces more balanced type I
error rates (42).
In 2005, Harbord et al. developed a test that maintains the power of the Egger test while
reducing the false positive rate, which is especially significant with the Egger test when
there is a large measurement value, small number of observations per trial or all trials are of
similar sizes (52). However, the original Egger test should be used instead of the Harbord
method if there is a large imbalance in size between studies.
Since the number of animals in our studies varies from 1 to 220 (see Figure 29), and also
considering the trade-off between power and type I error rates, we finally chose the original
Egger test for our analysis. An asymmetry score is calculated as the ratio of intercept for the
regression line to average value for the measurements in the group under analysis.
Asy =

intercept
average_value
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Figure 16 Publication Bias Examination Demonstrations for Body Weight

2. 4

Optimal Number of Experiments for Meta-Analysis Quality Control

To assure the quality of meta-analysis, we need to assign a confidence level to our metaanalysis model (here we used a binary parameter with value “confident” and
“low_confidence”) and results given a specific set of phenotype measurement data (in a
single meta-analysis). While each meta-analysis is based on a unique phenotype-strain pair,
for different phenotype-strain pairs, the total number of experiments can vary significantly.
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Hence, we examined the relationship between Asymmetry score (Asy) from publication bias
analysis and total number of experiments (in a single meta-analysis) to identify potential
biases in our analysis. The example below used Body Weight data (Figure 17, Figure 18). The
result shows that the Asymmetry score (Asy) was reduced significantly with four or more
experiments in one meta-analysis.

Figure 17 Relationship between Asymmetry Score and Total Number of Experiments for Body Weight
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Figure 18 Relationship between Range and Total Number of Experiments for Body Weight

We also examined range distribution and its relationship with the total number of
experiments (in a single meta-analysis). Figure 17 shows that data range for different metaanalysis datasets also varies with total number of experiments for each meta-analysis. The
range is defined as the difference between maximum value among all studies and minimum
value among all studies. For a meta-analysis with fewer experiments, the range between
studies can be falsely small. This indicates that meta-analysis without enough experiments
might have false negative heterogeneity representations (heterogeneity not revealed) and
thus the meta-analysis model choice might be wrong (fixed-effect or random-effect).
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2. 5

Sensitivity Analyses with Forest Plot

Data with poor quality for non-systematic reasons is often an issue in meta-analysis so
selection, inclusion and integration (or population stratification) of data is an important
factor for consideration. Those decisions may affect major findings, so researchers usually
carry out some sensitivity analysis prior to integration of data. The usual way of displaying
data for sensitivity analysis is by a forest plot. This displays the findings from each individual
study using a blob or square (53), the x-axis is the value of measurement or effect size. The
size of the blob or square is proportional to the sample size. A horizontal line representing
95% confidence interval is drawn around each of the studies’ squares to represent the
uncertainty of the measurement. The meta-analysis result is displayed as a diamond.
After exploring the forest plot of the study cohort, the main findings can be changed by
varying the approach to integration (or population stratification). An effective sensitivity
analysis will explore the effect of excluding various categories of studies, such as outlier data
(outliers need to be excluded for justifiable reasons), data without specified sex information,
or data from unpublished studies. It may also examine how consistent the results are across
various subgroups (perhaps defined by subject population stratification, type of
measurement method or condition).
A useful sensitivity analysis is a series of repeated meta-analyses, usually omitting one study
at a time. A heterogeneity score is calculated and the meta-analysis model (fixed-effect or
random-effect) is also chosen based on the heterogeneity score. Such an ‘exclusion
sensitivity plot’ by Bax et al. (54) reveals any study/observation that has a particularly large
influence (outlier) on the result of the meta-analysis. An interactive interface in our tool
provides users with the ability to decide on inclusion/exclusion of any study/observation in
the meta-analysis before proceeding with the next step in the analysis. Additionally, users of
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the pipeline may identify subgroups in their data and may decide to adopt a modified
sensitivity analysis by excluding a group of studies/observations and creating new
stratification criteria. For example, users may find substrain A/X and A/Y to have different
measurements for phenotype T. Instead of analyzing phenotype T using all data for strain A,
users may want to further stratify the population using substrain characteristics. Figure 19
shows an example of sensitivity analysis that identified the study result (in red circle) to be
an outlier. The example is for the F344 strain Body Weight phenotype. After initial analysis,
we found that the large value of the outlier is due to sample age. 65 days might not be a
homogenous group member for young rat group in terms of Body Weight although it might
be acceptable for another phenotype.
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Figure 19 Sensitivity Analysis Example Before Outlier Removal (Left) and After Outlier Removal (Right)

2. 6

Statistical Meta-Analysis

1) Heterogeneity and Meta-regression
In the meta-analysis, we needed to evaluate whether the results from different studies can
be “combinable”. This involved examining heterogeneity. Statistics commonly used for
testing heterogeneity include Cochrane’s Q ( Q 
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(55, 56). The Weight for each study is 𝑤𝑖 = s 2, where si is the standard deviation of that study. ES
i

represents effect size, which is a key concept in meta-analysis when assessing heterogeneity.
It aims to offer a standardized heterogeneity comparison among different measurements,
similar to the idea behind the t-test. It can be calculated as ES 

X
when the original
s

measurement value is used for meta-analysis. In our analysis, the Q statistic was unsatisfactory
as it depends heavily on the scale of measurement and has no absolute interpretation for
comparison. Thus the I2statistic was more attractive because it scores heterogeneity
between 0% and 100%, with 25% corresponding to low heterogeneity, 50% to moderate
and 75% to high (57). It interprets the percent of the total variance that is due to between
study heterogeneity. However, both methods may sometimes fail to detect heterogeneity
when it is actually present (58).
If the study results for a sub-population are relatively homogenous, we can integrate the
results using a general meta-analysis method (fixed-effect model). If heterogeneity exists,
we can further stratify the current sub-population based on a conceptual stratification
method (e. g. stratify based on age and sex) or use random-effect model meta-analysis. At
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this point, it is important to investigate what may have caused the heterogeneity. Metaregression is a technique which allows researchers to explore factors contributing to the
heterogeneity (59, 60). The simplest type of meta-regression uses summary data from each
entry, such as the average effect size, age, sex, experimental condition, and experimental
method. The result from the meta-regression provides us with useful insights on how to
further stratify sub-populations. This approach is valuable, but it has only limited ability to
identify significant factors (61). If no factors were identified, that means there might be
systematic differences between studies, leading to heterogeneity. Then we would need to
define special statistical parameters (inter-study variance used in random-effect model) to
interpret the systematic heterogeneity of the results.
2) I2 Statistics Cut-off Threshold
In the previous step, we decided to exclude or take a lower confidence in meta-analysis
when the total number of experiments was below four. In this step, we needed to decide
the cut-off threshold for the I2 statistic to decide the model choice for each meta-analysis. In
the example in Figure 17, we can see that I2=0. 85 is an optimal cut-off threshold to separate
high and low heterogeneity datasets. The four quadrants in Figure 17 represent different
characteristics of datasets for each meta-analysis task. Quadrant one represents a high
asymmetry score and high heterogeneity, which may be caused by publication bias or true
heterogeneity (e. g. extreme outliers). Quadrant two represents a high asymmetry score and
low heterogeneity, which may indicate true publication bias. Quadrant three represents a
low asymmetry score and low heterogeneity, which indicates that we should choose the
fixed-effect model. Quadrant four represents a low asymmetry score and high
heterogeneity, which indicates that we should choose the random-effect model. From this
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summary plot, we can determine model choice for data in Quadrant three and four. For
data in Quadrant one and two, we need to further confirm the existence of publication bias
before any conclusions can be made.
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Figure 20 Scatter Plot of Asymmetry Score and I2 statistics for Different Meta-Analysis Results for Body Weight Data (x: Asymmetry Score; y: I2 statistics)

3) Fixed-Effect Model vs Random-Effect Model
The presence or absence of heterogeneity influences the subsequent method of analysis. If
heterogeneity is absent, then the analysis employs a fixed-effect model. This assumes the
size of the system effect is fixed across all studies and the variation seen between studies is
completely random. However, as studies generally vary in size and variance, each study is
considered to have different precision. In meta-analysis, the key concept is to assign a
weight to each study while synthesizing results. Generally believed by statisticians, a study
based on 100 subjects is assumed to provide a more “precise” estimate than a study based
on 10 subjects. Therefore, larger studies should carry more “weight” in the analyses than
smaller studies. This sample size based approach is a simple one. A better approach is to
1

assign weight by the inverse variance (𝑤𝑖 = s 2). Thus, the meta-analysis mean is mw =
i

∑i wi yi
⁄∑ w and variance var(mw ) = 1⁄
.
i i
√∑i wi
Ideally, population stratification should be sufficient for removing heterogeneity, and we
should be able to construct our meta-analysis model with the fixed-effect model only. This
should hold true in many cases as long as k (number of studies) and the within study sample
sizes are large. In practice, k and sample size are usually not very large, so the estimate of
variance may be too small, because when calculating variance var(mw ), we ignore the
variability in the weights, assuming weights to be fixed and known. However, in some cases,
there may be latent factors contributing to the variance between studies. Thus,
heterogeneity cannot be removed through further stratification. Several alternative
approaches have been proposed to address this issue, including the weighted least squares
approach (62) and the robust variance estimator (63). Both estimators perform better than
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the original model, with the robust variance estimator a little better overall (63, 64). The
robust variance estimator estimates the variance as var(mw ) =

∑ wi (yi −mw )2
∑ wi (k−1)

.

Another more commonly used way is to adopt a random-effect model. Random-effect
models assume that the treatment effect varies between studies. The observed
measurement yi , from the i-th study is made up of two additive components: the true
measurement, θi , and the sampling error, ei . That is, yi =θi +ei for i=1, …, k. The variance of
ei , can be estimated by si 2 . Additionally, inter-study variance has to be considered in the
formula. The first and most widely adopted random-effects models for meta-analysis was
proposed by DerSimonian and Laird in 1986 (65). This method is now considered the
“standard approach” for meta-analysis in medical and clinical research. In their model, they
also adopted inverse variance weight. The total variance, however, is the sum of within1

study variance (si 2 ) and inter-study variance (τ2 ), leading to weight as 𝑤i = τ2 +s 2 . τ2 which
i

can be obtained using three methods: maximum likelihood (ML), restricted maximum
likelihood (REML), and method-of-moments (MOM). The author compared the three
methods and concluded that ML was biased downward, and that there was little difference
between REML and MOM (66). They used MOM because it is non-iterative and easy to
implement (ML and REML requires iteration to estimate τ2 ). A general method-of-moments
estimate t 2 for τ2 is:
[∑i ai (yi − yw )2 ] − [∑i ai si 2 −

∑i ai 2 si 2
⁄∑ ]
i ai

t2 =
[∑i ai −

∑i a i 2
⁄∑ a ]
i i
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where a1 , … , ak are positive constants reflecting weights assigned to the k studies. Each set
of a1 , … , ak values will yield an alternative estimate for τ2 . In DerSimonian and Laird's (65)
1

non-iterative estimate, t 2 (DL), ai = s 2 .
i

Further studies have compared DerSimonian and Laird’s method with several more
computer intensive methods (67-69). These estimators include Cochran's (70) analysis-of1

variance (ANOVA) non-iterative estimate, t 2 (CA), where ai = k ; Paule and Mandel's (71)
iterative estimate, t 2 (PM), where ai =
estimate of τ2 , t 2 (CA2), where ai =

1
2
t2 (PM)+si

1
t2 (CA2)+si

2

; two-step estimate starting with Cochran's

; and two-step estimate starting with the

DerSimonian and Laird estimate of τ2 , t 2 (DL2), where ai =

1
2
t2 (DL2)+si

. They found that

DerSimonian and Laird’s method is sufficient in most cases. Actually several more
sophisticated estimators for both iterative and non-iterative methods can be considered as
special cases of a general DerSimonian and Laird’s method with a slightly different formula
to calculate weights assigned to the individual studies (67). To achieve both efficiency and
performance, in this study, we used the original non-iterative DerSimonian and Laird
estimator for τ2 .

2. 7

Meta-Analysis Workflow and Example

The previous sections described the analysis methods we used to determine parameters in
the meta-analysis workflow. A decision tree of the workflow is shown in Figure 21.
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Figure 21 Meta-Analysis Workflow

In summary, our workflow is composed of the following key steps:
1. Perform exploratory analysis (Figure 21 (b)) to examine publication bias and total
number of experiments. For examination of publication bias, we used the original Egger
test considering the trade-off between power and type I error rates. |Asymmetry
score| > 1. 5 or total number of experiments <4 is a sign of a potentially biased sample.
Thus, conclusions from the meta-analysis might not be trustworthy. We will need to
acquire more data in order to proceed with the analysis. In Figure 22, we showed an
example of publication bias. The |Asymmetry score| is > 1. 5 from Egger Galbraith plot.
In the Egger funnel plot, there is a clear bias towards publication of heavier rats.
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Figure 22 Publication Bias Exist for BN Body Weight Measurement

2. Perform exploratory analysis (Figure 21 (c)) to determine inclusion/exclusion of
individual study/observation in the meta-analysis. An example is provided in Figure 19.
3. Examination of heterogeneity (Figure 21 (d)) using Cochrane’s Q
(Q 
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statistic (𝐼 = {
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× 100% 𝑓𝑜𝑟 𝑄 > (𝑘 − 1)
). For each set of experiments
0 𝑓𝑜𝑟 𝑄 ≤ (𝑘 − 1)

qualified for meta-analysis, we calculated Q and I2, which were used to determine
model selection in the next step.
4. Choosing meta-analysis model (fixed-effect or random-effect). The fixed-effect and
random-effect model choice threshold is set to I2=0. 85, which is considered the
optimal threshold to distinguish heterogeneity caused by a limited number of records
or true inter-study variance.
For the fixed-effect model, meta-analysis mean is mw =

∑i wi yi
⁄∑ w and variance
i i

1
var(mw ) = 1⁄
(𝑤i = s 2 ).
i
√∑i wi

For the random-effect model, since results show that DerSimonian and Laird’s method
is sufficient in most cases, in this study, we used the original non-iterative DerSimonian
∑ a 2s 2
[∑i ai (yi −yw )2 ]− ∑i ai si 2 − i i i ⁄∑ a
i i
1

[

and Laird estimator for τ2 . Thus 𝑤i = τ2 +s 2 and τ2 =
i
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∑ 2
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Based on the original model estimator, the meta-analysis mean is mw =

]

∑i wi yi
⁄∑ w
i i

and variance var(mw ) = 1⁄
.
√∑i wi
An example of random effect model is shown in Figure 23. It shows that the I2=0. 871>0.
85. Using fixed-effect model, the meta-analysis value will be 121. 17. However, using
the random-effect model, the meta-analysis value will be 128. 57.
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Figure 23 Random-Effect Model for BN "Systolic Blood Pressure"

5. All the summary values for the phenotype under analysis are displayed in a summary
forest plot (shown in Figure 24). The center of the box represents the meta-analysis
mean and the range determined by one standard deviation above and below the metaanalysis value. The color of the boxes showed the total number of experiments that
made up of the meta-analysis range. It is a sign of confidence for the resulting
phenotype range. On the right side, the legend shows the strain and sex of which the
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range is representing. In the bracket, we also noted the confidence level of analysis
considering the total number of experiments (<4 low_confidence, >=4 confident).

Figure 24 Meta-Analysis Final Summary for “Systolic Blood Pressure” (Male)

2. 8

Applications of Meta-Analysis in the Biomedical Field

Since the publication of DerSimonian and Laird’s paper (65), the paper has been cited 19,
145 times according to Google Scholar with more than 50% of those citations occurring in
the last few years. Their approach to integrate the findings across related clinical trials has
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become increasingly popular in medical research. According to a recent survey done by
DerSimonian (66), the top five research topics constituting about half of the total 7, 342
citations during 2010–2014 are in oncology (17%), internal medicine (12%), science &
technology (8%), cardiology (7%) and surgery (7%). For example, Ruff et al. compared the
efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation
using DerSimonian and Laird’s method (72). Beelen et al. examined the effects of long-term
exposure to air pollution on natural-cause mortality by performing meta-analysis on 22
European cohorts within the multicentre ESCAPE project (73). Recently, meta-analysis was
even used to combine multiple different genome-wide association (GWAS) studies in a
single integrated analysis in order to identify associations with very small effect sizes (74).
The list of meta-analysis applications in the biomedical field is exhaustive showing that
applying the meta-analysis method to generate standard phenotype measurement ranges is
justified and may provide significant insights from rat phenotype data.

2. 9

Limitations of Meta-Analysis

Meta-analysis is an effective method to integrate data from heterogeneous data sources,
with different sample sizes or even different sub-populations/substrains. Such cases include
clinical treatment effectiveness test, drug safety evaluation, and effect of diet and exercise
on physiological representations, etc. However, it has some limitations:
1. If publication bias is identified, in a preliminary stage, there currently are no statistical
methods to overcome this bias and its affects. The existence of publication bias means
that any conclusions made might be biased so that meta-analysis results might not reach
sufficient levels of confidence. Therefore, researchers who would like to conduct meta-
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analysis with a biased dataset need to be aware of and fully disclose the existing
publication bias when they make conclusions.
2. Meta-analysis quality and confidence are fundamentally limited by the quality of the
underlying studies, so it is necessary for the researchers to evaluate the quality of data
by examining the sample size of each experiment, the institutes’ credibility, the
protocols they used to perform analysis, and other details before meta-analysis can be
conducted.
3. Random-effects models tend to increase the variance of the summary measure, making
it more difficult to obtain significant results. When the amount of heterogeneity is large,
it may even be inappropriate to calculate an overall summary measure of effect size.
4. The results of several meta-analysis studies were later compared to large-scale, wellconducted, randomized controlled trials (so-called ‘mega trials’). Some showed good
agreement between meta-analysis results and mega trial results while others showed
discrepancies (75, 76).
In conclusion, it is extremely important to be diligent at every step while conducting metaanalysis, to examine data patterns to make sure no publication bias exists, to carefully
examine the cause of heterogeneity if there is any, and finally to choose a model based on
data patterns.

2. 7

Data Source Overview

RGD implemented the PhenoMiner project (29) to integrate quantitative phenotype data
from the PhysGen Program for Genomic Application (24), the PhysGen Knockout Project (30)
and the Rat Phenome Project (20) under National Bio Resource Project (NBRP) (77) in Japan
as well as data from publications or submitted by researchers. This combined data includes
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56,710 active entries in the PhenoMiner tool (28). PhenoMiner includes data for 1,218
strains (including substrains), and 678 phenotype parameters (248 under naïve control
conditions) across neurobehavioral, cardiovascular, biochemical, hematological and
morphological categories (78). Entries are grouped by experiment within a study. For some
studies, such as NBRP or PhysGen, numerous experiments make up the study while in
others, such as those from a publication, a study may only be comprised of two or three
experiments. Figure 25 provides some insight on the wide spread use of some strains, such
as SHR, SS, FHH, as disease models and WKY as a control model. Figure 26 shows that a
majority of entries in PhenoMiner comes from Study 41 (NBRP Organ Weight). Figure 27
further illustrates the large number of quantitative phenotype records available for strains
used as cardiovascular disease. Organ weight records are also numerous in PhenoMiner and
are mostly from Study 41 (NBRP Organ Weight) and Study 21 (NBRP Body Weight) in which
morphological measurements were a primary focus.
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Figure 25 Number of Entries per Strain Group in PhenoMiner Database
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Figure 26 Number of Entries per Study in PhenoMiner Database
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Figure 27 Number of Entries about Organ Weight by Study in PhenoMiner Database

From Figure 28 we can see that the majority of phenotype records in PhenoMiner are for
organ weights and cardiovascular phenotypes. This is in accordance with the fact that rats
are widely used in cardiovascular research.
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Figure 28 Number of Entries per Phenotype in PhenoMiner Database
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Figure 29 shows the number of experiments utilizing particular sample sizes. As might be
expected, a sample size of 6 was the most numerous since every experiment in NBRP has
used 6 animals. As we mentioned previously, the number of animals in each study range
from 1 to 220. Overall, there are more small-scale studies than large ones.

1000

2775
900
800
700

Count

600
500
400
300
200
100
0
1

6

11 16 21 26 31 37 43 49 55 61 69 75 84 90 95 107 208 220
Number of Animals

Figure 29 Number of Experiments with Particular Sample Sizes in PhenoMiner

We also separately analyzed sequenced strains and non-sequenced strains (Table 2 shows a
sub-section of our table). From the analysis we found that on average, sequenced strains
have more than double the phenotype measurements than non-sequenced strains (Figure
30). This is in line with the fact the community promoted particular strains to be sequenced
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based on their wide usage as disease models or controls. The availability of the sequence
would provide additional resources to link phenotypes to genotypes. The table also provides
us with insight on what phenotypes to acquire from research labs in the future to fill in gaps
and provide sufficient data for analysis and what strains to sequence given the abundance
of phenotype data that already exists. Such efforts would expand the resources available for
researchers to investigate the impact of genotype on phenotype. Our analysis shows that
the strains ACI, BUF, DA, and SHRSP are lacking some data on blood chemistries related to
cardiovascular physiology which could supplement their extensive data for heart and blood
pressure characterization including data on serum triglyceride level, plasma total cholesterol
level, plasma triglyceride level, and serum free fatty acids level which are important
metabolites in cardiovascular physiology (Table 2). Compared to systolic blood pressure and
mean arterial blood pressure, diastolic blood pressure data were less frequently available
for the PhenoMiner project. Such findings could help the PhenoMiner project group to focus
on acquiring data from targeted publications or individual researchers in order to fill out
comprehensive phenotype profiles for strains. Among non-sequenced strains, we found
MWF has a considerable amount of data related to renal function and blood chemistry
phenotypes. Findings such as these could also help to focus on acquisition of data from
other phenotype areas and to promote strains such as MWF as a candidate worthy of being
sequenced.
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Table 2 Summary of Cardiovascular Phenotypes for Sequenced Strains
Phenotype

ACI

BN

WKY

BUF

DA

F344

FHH

GH

LE

LEW

SHR

SHRSP

SS

heart rate

ACI

BN

WKY

BUF

DA

F344

FHH

GH

LE

LEW

SHR

SHRSP

SS

systolic blood pressure

ACI

BN

WKY

BUF

DA

F344

GH

LE

LEW

SHR

SHRSP

SS

heart wet weight

ACI

BN

WKY

BUF

DA

F344

FHH

GH

LE

LEW

SHR

SHRSP

SS

heart weight as percentage of body weight

ACI

BN

WKY

BUF

DA

F344

FHH

LE

LEW

SHR

SHRSP

SS

mean arterial blood pressure

BN

WKY

F344

FHH

LE

LEW

SHR

SHRSP

SS

diastolic blood pressure

BN

WKY

LEW

SHR

SHRSP

heart right ventricle weight to left ventricle weight ratio

BN

WKY

LEW

SHR

BN

WKY

BN

heart weight to body weight ratio

ACI

GH
F344
DA

F344

WKY

DA

F344

heart left ventricle weight to body weight ratio

WKY

DA

F344

heart right ventricle wet weight

WKY

heart left ventricle wet weight

52

hematocrit

ACI

serum total cholesterol level

BN

WKY

BN

WKY

GH

BUF

FHH

GH

LE

SHR
GH

LEW

SHR

LEW

SHR

SS
SHRSP

F344
BUF

DA

F344

FHH

GH

LE

LEW

SHR

SHRSP

SS

DA

F344

FHH

GH

LE

LEW

SHR

SHRSP

SS

blood hemoglobin level

ACI

BN

WKY

BUF

DA

F344

FHH

GH

LE

LEW

SHR

SS

red blood cell count

ACI

BN

WKY

BUF

DA

F344

FHH

GH

LE

LEW

SHR

SS

mean corpuscular volume

ACI

BN

WKY

BUF

DA

F344

FHH

GH

LE

LEW

SHR

SS

serum calcium level

BN

WKY

F344

FHH

GH

LE

LEW

SHR

SS

serum aspartate aminotransferase activity level

BN

WKY

F344

FHH

GH

LE

LEW

SHR

SS

serum potassium level

BN

WKY

F344

FHH

GH

LE

LEW

SHR

SS

serum chloride level

BN

WKY

F344

FHH

GH

LE

LEW

SHR

SS

serum triglyceride level

BN

DA

F344

SHR

plasma total cholesterol level

LEW

plasma triglyceride level

LEW

serum free fatty acids level

F344
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Figure 30 Average Number of Phenotype Measurements for Sequenced Strains and Non-Sequenced
Strains

To evaluate potential heterogeneity in phenotype measurements, we also investigated the
methods used to measure each phenotype. We found 191 phenotypes with only one
measurement method and 52 phenotypes with records divided among two or more
measurement methods (Figure 31). Phenotypes such as systolic blood pressure were
measured using seven different methods (shown in Figure 32). As PhenoMiner developed, it
was evident that measurement method had an impact on values collected, something that
was commonly known among researchers but had not been quantified. We found that
measurement methods used also correlated with ages of rats in experiments at times. For
example, it is hard to measure younger rats with the intra-vascular method for blood
pressure; hence younger rats are usually measured using tail cuff methods. Because of the
impact of measurement method on the value of the measurement, it is one of the
parameters used to group and stratify records within phenotype areas.
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Phenotype Measurement Method

21%
One method
Two+ methods

79%

Figure 31 Number of Phenotypes Measured by One or More Than One Method

Figure 32 Percentage of Phenotype Records for Systolic Blood Pressure by Measurement Type

2. 8

Meta-Analysis Result and Evaluation

Our meta-analysis analysis provided expected ranges for 24 cardiovascular related
phenotypes. We analyzed all the available sequenced strains for each phenotype. For nonsequenced strains, we focused on MWF since most non-sequenced strains had limited data
available for these phenotype areas.
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In the first step, our meta-analysis used only experiment records under control conditions
for inbred stains. In this way, the meta-analysis range can be regarded as an “Expected
Range” for a specific strain or strain group. One type of strain group was created by
grouping all substrains under a certain parent strain name according to the Rat Strain
Ontology. In accordance with official standards, a strain is given a substrain designation
when it is bred for 20 generations or more in a different facility or laboratory. For example,
strain group “ACI” include all substrains “ACI/Eur”, “ACI/Kun”, “ACI/N”, “ACI/SegHsd”,
“ACI/Ti”, “ACI/Ztm”. Control strain groups were also created based on their widespread use
as control animals and acceptance as exhibiting “normal” measurements. For example, the
“Normal Systolic Blood Pressure Strain Group” consists of strains that are considered
commonly used as controls in blood pressure experiments and to exhibit “normal systolic
blood pressure”. The “Normal Systolic Blood Pressure Strain Group” was created in an
iterative process using a domain expert with extensive experience in large scale
phenotyping projects: 1. Strains commonly used as controls were identified based on
experience and prior knowledge and designated as “founder control strains” e. g. BN and
WKY which have long been used as control models. 2. An initial “Expected Range” was
constructed based on phenotype ranges of those “founder” strains using the highest and
lowest values of the previously determined expected ranges for each strain. 3. The overlap
of previously determined expected ranges of other strains with this initial “Control
Expected Range” was examined to determine whether additional strains could be included
in the normal phenotype strain group. 4. An updated “Control Expected Range” was
constructed using all strains added to the normal phenotype strain group.
In addition to constructing a general “Expected Range”, we stratified our analysis by age,
sex, and measurement method when data was available for different ages, sexes, or
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methods. We then constructed age, sex, method-specific “Expected Ranges” using the
same workflow. The results of constructing phenotype “Expected Ranges” are discussed in
the first section below.
After the initial “Expected Ranges” for 24 phenotypes using inbred strains were
constructed, we also performed meta-analysis for outbred and mutant strains, when
sufficient data existed. We also evaluated the applicability of the analysis under noncontrol conditions using inbred strains in which a measured salt diet was the experimental
condition. Creating such expected ranges for particular experimental conditions will further
assist researchers in choosing model strains for particular experiments and provide data for
developing tools and statistical processes that would allow them to analyze their own data.
1) Phenotype Expected Ranges
Phenotype data was available for inbred, outbred, consomic, congenic, mutant and
transgenic strains. However, for this study, initial development of the algorithms and
workflows and expected ranges of phenotypes were established using only inbred strains. In
addition, phenotype records in which the experimental conditions naïve control, were used
and those involving experimental diets, exercise, application of drugs or chemicals or other
manipulated conditions were not initially used in this study. Figure 33 shows an example of
a forest plot summary produced for “systolic blood pressure” for different age groups. We
were then able to identify strains with expected ranges within or have overlap with
previously constructed “Control Expected Range” (ACI, BN, BUF, DA, F344, GK, LE, LEW, LN,
M520, MNS, MR, MWF, and WKY), and strains with expected ranges outside of the
constructed “Control Expected Range”(GH, LH, MHS, SHR, and SHRSP), strains for naïve
control (BN, WKY) from the graph.
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Figure 33 Forest Plot of Meta-Analysis Summary for “Systolic Blood Pressure”

APPENDIX A includes all the meta-analysis summaries for 24 cardiovascular phenotypes
(blood hemoglobin level, diastolic blood pressure, heart left ventricle weight to body weight
ratio, heart left ventricle wet weight, heart rate, heart right ventricle weight to left ventricle
weight ratio, heart right ventricle wet weight, heart weight as percentage of body weight,
heart weight to body weight ratio, heart wet weight, hematocrit, mean arterial blood
pressure, mean corpuscular volume, plasma total cholesterol level, plasma triglyceride level,
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red blood cell count, serum aspartate aminotransferase activity level, serum calcium level,
serum chloride level, serum free fatty acids level, serum potassium level, serum total
cholesterol level, serum triglyceride level, systolic blood pressure). Information about
abnormal, normal, naïve control strains for 24 phenotypes is available in APPENDIX B.
We also created separate summaries for different age groups (age1: <70 days, age2: 70-99
days, age3:100+ days) and gender groups if significant age or gender difference was
observed in the all age analysis. For example, in Figure 33, systolic blood pressure between
male and female differs from each other and shows an obvious pattern (usually females has
lower blood pressure). After analysis, we decide that we should produce a separate
summary for both gender and for each age group as well. Same situation applies to
phenotypes such as diastolic blood pressure, heart weight as percentage of body weight,
heart weight to body weight ratio, heart rate, heart wet weight, and mean arterial blood
pressure. First, those phenotypes have enough data for age and gender stratification while
still produces meaningful meta-analysis results. Phenotypes related to ventricle weight and
blood metabolite measurement suffer from lack of data for stratification (heart right
ventricle weight to left ventricle weight ratio, heart right ventricle wet weight, plasma total
cholesterol level, plasma triglyceride level, serum aspartate aminotransferase activity level,
serum calcium level, serum chloride level, serum free fatty acids level, serum potassium
level only have data for one age group).
Results from the meta-analysis were reviewed by a domain expert who previously had
classified strains potentially within and outside of predicted reference ranges of “normal”
and outside of “normal” based on wide spread use and characterization as control and noncontrol strains. Disagreements between the meta-analysis results and the domain expert’s
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classification were marked out on the graph with a red rectangle. The percentage of cases in
which there was consistent agreement were calculated at 98% (APPENDIX C).
We also found that for some strains considered to exhibit “normal” phenotypes, although
the meta-analysis mean value was within the overall expected range, the upper bound or
the lower bound of its individual range was beyond the overall expected range for “normal”,
perhaps indicating 1) more data is needed from more institutes for more confident
conclusions about individual expected ranges, or 2) variability for those strain groups may
be due to potential genetic drift so that the genotypes of substrains have become more
diverse or certain strains could be more susceptible to outside influences such as housing,
handlers and other environmental factors on phenotypes. A good example would be
ACI_Female, BUF_Male and WAG_Female/Male/Both in Figure 33. We also found that the
obvious pattern between male and female (usually females has lower blood pressure)
sometimes didn’t hold true. For example, in Figure 34, SHRSP the sex specific pattern is
opposite of the common pattern where female rats have lower blood pressure than male
rats. On the other hand, SHR exhibits the common pattern.
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Figure 34 Summary for "Systolic Blood Pressure" Shows Sex Pattern Does Not Always Hold True

Summary data which stretched beyond the overall expected ranges or exhibited odd
patterns generally came from meta-analyses with a limited number of experiments (usually
<5). This is evidence of low confidence for the meta-analysis result, which indicates more
experimental data are needed to establish a trustworthy range. This is also evidence that for
meta-analysis, the number of studies included is vital to eliminate random experimental
error and generate trustworthy results. The number of studies in general was more
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important than the number of animals in each study. Our analysis method demonstrated its
potential to be used: 1) to provide expected ranges for rat phenotypes; 2) to facilitate
research planning by visualizing current gaps and suggesting potential research directions to
fill in the gaps.
2) Rat Strain Model Comparison
Initially, expected ranges for individual phenotypes were established for inbred strains
under the naïve control condition. We then applied the analysis process calculate expected
ranges for phenotype measurements for outbred, mutant, congenic and transgenic strains.
Next, we calculated expected ranges for inbred, outbred, mutant, congenic and transgenic
strains on measurements acquired under different diet conditions. As we developed the
analysis pipeline, we created a user-friendly interface, so researchers could compare
expected ranges for different rat models under both control and salt diet conditions. (inbred,
outbred, mutant, congenic and transgenic; naïve control vs salt diet).
Outbred and Mutant Strains

Figure 35 shows expected ranges for “systolic blood pressure” under naïve control
conditions for outbred and mutant rat strains. The dotted lines represent the expected
range for the “Control Strain Group” based on 14 inbred strains used as controls for this
phenotype. This presentation clearly indicates which strains have expected ranges within
the “normal” control range and which do not.
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Figure 35 RGD Phenotype Expected Ranges for “Systolic Blood Pressure” for Outbred and Mutant
Strains

2. 9

Tools to Mine and Present Expected Ranges

While the determination of expected ranges for individual phenotypes within specific strains
and across strains is a valuable resource, data mining and visualization tools increase the
value of this resource for investigators. Modifications to existing database structures and
the development of query and visualization tools make this possible.
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1) Database Structure
The existing PhenoMiner database structure (Figure 36) was modified to incorporate the
expected range values for each strain group. The tables with alternating shaded cells are
newly added TABLEs. EXPECTED_RANGE TABLE was created to store data for phenotype
expected ranges. EXPECTED_RANGE_EXPERIMENT_REC TABLE links the experiment records
that make up the phenotype expected ranges to the expected ranges. STRAIN_GROUP
TABLE was created to link the strains that make up the phenotype expected ranges which
may be several substrains or substrains and parent strain, or that the designated control
strains to create the “normal” or control expected range for that phenotype.

Figure 36 Data Structure for Storing Expected Range Data
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2) Home Page and Query Tool
To highlight the results of the meta-analysis and provide tools to mine and display data, a
component for the Rat Genome Database has been created. The query begins with a search
by trait area in a pulldown menu at the top right corner of the home page (Figure 37). This
results in a listing of the quantitative phenotype measurements commonly used to assess
aspects of that trait area. In the example provided, circulatory system trait, the phenotypes
presented include systolic, diastolic and mean arterial blood pressure, various weight
measurements for the heart and heart rate. For each phenotype, the normal range that was
calculated from control strains is presented in a table. The table also includes 1) number of
strains with available expected ranges; 2) number of strains with sex-specific expected
ranges (at least two expected ranges for mixed, female, or male, so that expected ranges
can be compared between sex groups); 3) number of strains with age-specific expected
ranges (at least two expected ranges for 0-79 days, 80-99 days, or 100+ days, so that
expected ranges can be compared between age groups).

1

2

3

Figure 37 Summary of Number of Strains with Expected Ranges (Circulatory System Trait)
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The user can click on the phenotype term or the number of strains value to retrieve the
associated data. For example,
clicking on the term Diastolic Blood
pressure or Circle 1 retrieves all
expected ranges of available
strains for diastolic blood pressure;
clicking on Circle 2 retrieves
expected ranges for the 7 strains
that for which there are separate
ranges for each sex for diastolic
blood pressure; and clicking on
Circle 3 Retrieves the data for the
9 strains for which there are
separate expected ranges for
multiple age groups.
We also provided a listing of
Figure 38 Summary of Number of Phenotypes with
Expected Ranges (Circulatory System Trait)

number of expected ranges of
(circulatory system) phenotypes

available for each strain (Figure 38).
3) Data Summaries and Visualization
Retrieved data are presented in an interface that includes three major components: a
selection panel, a visualization panel and a data panel (Figure 39).
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The selection panel built with a bootstrap JavaScript library (https://getbootstrap. com/)
provides the user with the information on the strains, measurement methods, experimental
conditions, sex and age groups associated with the returned data, This allows the user to
further customize the returned data by narrowing the results to smaller strain sets, specific
measurement methods, ages or sex by clicking off the options not desired. As an initial
selection is made, options for further filtering are automatically updated to present those
available based on the initial selection. As Figure 40 shows, when the user chooses Age
Group 0-79 Days, the panel and visualization change to show that data is only available for
the SHR, SHRSP and WKY strain groups. Figure 41 presents the visualization when the user
limits the results to males only in the first step and Figure 42 when the user selects specific
strains in the first step.
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Figure 39 Entire Interface includes a selection panel, a visualization panel and a data panel
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Figure 40 Visualization of All Rat Strains’ Expected Range for Diastolic Blood Pressure (with selected age groups)
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Figure 41 Visualization of All Rat Strains’ Expected Range for Diastolic Blood Pressure (with selected sex groups)
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Figure 42 Visualization of All Rat Strains’ Expected Range for Diastolic Blood Pressure (with selected strains)

The visualization panel was created using Plotly (https://plot. ly/) and D3js (https://d3js.
org/) libraries. Each box on the chart shows the expected range for a phenotype
measurement based the parameters that constitute a record - strain group, sex, age,
method and experimental condition. The red dotted line provides a reference showing the
expected range that is considered a normal range for control groups. The user can choose to
show the overall reference expected range or that for either sex. Currently only ranges
under naive control condition are available in the tool with those already determined for
salt diets to be added. This tool easily illustrates for researchers which strains have large or
small expected ranges, which expected ranges for commonly used disease models actually
overlap expected ranges for control groups. As shown in Figure 39 and Figure 43 it can
easily be seen that MHS, MNS and SHR_Females have very large expected ranges that
overlap to an extent with normal ranges while the SHRSP strain exhibits narrow ranges and
all SHRSP expected ranges are above the normal range. Such information is useful when
investigators are designing research projects.
The legend on the right side is also clickable. By clicking on individual boxes on the right-side
legend list, one can choose to view or hide specific expected range.
Furthermore, users can choose to compare expected ranges for different strains against a
selected reference. We provide reference expected ranges for female rats only, male rats
only, rats with age 0-79 days, rats with age 80-99 days, as well as rats with age 100-999 days.
Age-specific references are not available for all phenotypes. The reference values can be
viewed at the bottom of the graph.
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Figure 43 Visualization of All Rat Strains’ Expected Range for Diastolic Blood Pressure (showing reference of Female Rats)

Below the box plot graph is the data panel where we included a table with all the details
(strains, measurement methods, sex, age, range mean, range SD, range low and range high)
of the visualized information. Users can look up the details of a specific data entry (box) by
searching its record ID in the table.

3 Rat Sub-Population Identification with Multiple Phenotype Profiles
In addition to providing access and tools to the determined expected ranges, additional
analyses can be conducted on these results to further identify disease models and groups of
strains appropriate for disease studies.
As noted rats are commonly used to study complex diseases such as cardiovascular,
endocrine and neurological diseases. Most of the disease phenotypes related to polygenic
(complex) diseases are continuous and are only considered abnormal when the
measurement value for the phenotype exceeds or is below a certain threshold. Moreover, a
number of phenotypes are affected in complex diseases, and the phenotypes that represent
a complex disease are usually correlated. However, those correlated phenotypes related to
a specific disease might have unique representation patterns in individuals. Heterogeneous
representations of phenotypes may indicate the existence of disease subtypes with different
biological mechanisms and may require different treatment plans. In addition, such
differences could indicate the influence of environmental factors on the expression of the
phenotype patterns.
Kim et al. showed that the 53 clinical phenotypes in the asthma dataset from the Severe
Asthma Research Program (SARP) (86) can be represented as a network with several densely
connected subnetworks (87). They leveraged a graph (Figure 44) of multiple asthma-related
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quantitative traits as prior
knowledge. From the assumption
that the densely connected
subgraphs over these correlated
traits are more likely to be
influenced by the same or heavily
overlapping subset(s) of SNPs,
Figure 44 Illustration of Association Analysis using
Phenotype Correlation Graph for Asthma Dataset (87)

regression analysis can be done to
examine relationship between the

quantitative traits in the subnetwork and causal SNPs subsets.
Rats are frequently used as cardiovascular disease models. Identifying complex disease subpopulations would further assist investigators in choosing appropriate models for their
research. For example, subtypes of hypertension such as isolated systolic hypertension (ISH),
isolated diastolic hypertension (IDH), and combined systo-diastolic hypertension (SDH) may
represent different mechanisms and may indicate different risks for future cardiovascular
events such as stroke and coronary heart disease (88). Furthermore, differences in organ
damage and co-morbidities exist among different hypertension subtypes including
hypertension accompanied by renal dysfunction, obesity, sleep apnea, or autonomic failure
(89).
Very limited research in the identification of disease sub-populations has been done in
model organism domain while there has been increasing interest in the clinical domain in
patient sub-population identification and patient similarity-based predictive modeling for
diagnosis and prognosis (90). Currently this interest is also extending to organisms used in
pre-clinical research, such as the rat. Developing well-defined comprehensive phenotype
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profiles for specific rat strains will enhance the ability of researchers to choose appropriate
models that mimic the phenotypic profiles of humans with a particular disease.
Currently clustering-based algorithms are the most commonly used methods to identify
disease sub-populations. Cluster-based algorithms also use distance measurement to
retrieve a group of similar subjects. Hence new subjects can be assigned to a predefined
cluster based on their similarity/distance to each cluster. Various types of similarity metrics
can be used to describe similarity between subjects, most of them are distance-based.
Distances are measured to quantify similarity between subjects to retrieve a sub-population
of similar subjects and find the closest class to a new subject. Distance measures include:
Absolute distances (the absolute distances between 2 and 5 is |2-5|=3), Euclidean distance
("ordinary" straight-line distance between two points in Euclidean space; DE
=

), Mahalanobis distance (a measure of the distance between

a point P and a distribution D;

, S is the covariance matrix).

We employed a clustering-based method to calculate rat strain similarity with Euclidian
distance to identify subpopulations of rat strains based on their phenotype profiles as
determined by expected ranges. Using strain, experimental condition and multiple
quantitative phenotypes as features, our cluster-based approach identified sub-populations
with different profiles in a general disease category. The resulting model represents various
rat population subtypes.
The algorithm was implemented using Weka (91). Weka is a collection of machine learning
algorithms for data mining tasks. The algorithms can either be applied directly to a dataset
or called from your own Java code. Weka contains tools for data pre-processing,
classification, regression, clustering, association rules, and visualization. Here we used a
standalone Weka java application for data pre-processing, clustering, and visualization.
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3.1

Material and Method

1) Data Source
The data used for clustering included the meta-analysis expected range values for five
cardiovascular related phenotypes: mean arterial blood pressure, diastolic blood pressure,
systolic blood pressure, heart rate, and heart wet weight.
2) Model Construction
Hierarchical clustering was conducted using a method with Euclidian distance as the
similarity measurement method. The algorithm was implemented using Weka (91).
3) Model Selection
We used subsets of data with different numbers of phenotype features to construct our
clustering model. We then compared the “Distinguish Power” of each model to select the
best clustering model. “Distinguish Power” is defined as the ratio of number of clusters to
wrong cluster assignments (or small clusters with only one member). The Gold standard of
cluster membership was provided by RGD curators. The number of cluster k was also
selected based on the “Distinguish Power” metric. Small clusters were merged into big
clusters so that k was considered the optimal number of clusters. The results of the models
and respective scores are listed in Table 3 (items marked with * represent wrong cluster
assignment). Five phenotypes were numbered as mean arterial blood pressure (1), diastolic

blood pressure (2), systolic blood pressure (3), heart rate (4), and heart wet weight (5).
Table 3 Clustering Results and Distinguish Power for Different Models
Model

Cluster

1+2

WKY_Both, WKY_Female, WKY_Male, BN_Both, BN_Male,
LEW_Both*, LEW_Female*, LEW_Male*
SHRSP_Both, SHRSP_Male, SHRSP_Female, SHR_Female*
SHR_Both, SHR_Male, GH_Both, GH_Male
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Distinguish
Power
3/4

2+3

WKY_Both, WKY_Male, WKY_Female, MNS_Both, LN_Both, LEW_Both*,
LEW_Female*, LEW_Male*, BN_Both, BN_Male
SHRSP_Both, SHRSP_Female, SHRSP_Male, GH_Both, GH_Male,
SHR_Both, SHR_Male
SHR_Female*, MHS_Both*
WKY_Both, WKY_Female, WKY_Male,
LEW_Both*, LEW_Female*, LEW_Male*, BN_Both, BN_Male
SHRSP_Both, SHRSP_Male, SHRSP_Female, SHR_Both, SHR_Male,
GH_Both, GH_Male
SHR_Female*
WKY_Both, WKY_Female, WKY_Male, BN_Both, BN_Female, BN_Male,
F344_Both, F344_Female, F344_Male, FHH_Both, FHH_Female,
LE_Both, LE_Female, LE_Male, LEW_Both*, LEW_Male*, SS_Both,
SS_Female,
SS_Male, SHR_Female, SHRSP_Both, SHRSP_Male, SHRSP_Female,
SHR_Both, SHR_Male, GH_Both, GH_Female, GH_Male
FHH_Male*
LEW_Female*
WKY_Both, WKY_Female, WKY_Male, BN_Both, BN_Female, BN_Male,
F344_Both, F344_Female, F344_Male, LE_Both, LE_Male, LE_Female,
LEW_Both*, LEW_Male*, FHH_Both, FHH_Female, FHH_Male,
SS_Both, SS_Female, SS_Male, SHRSP_Both, SHRSP_Female, SHRSP_Male,
SHR_Both*, SHR_Female*
SHR_Male, GH_Both, GH_Female, GH_Male
LEW_Female
WKY_Both, WKY_Male, WKY_Female, BN_Both, BN_Male
SHR_Female*
SHRSP_Both, SHRSP_Male, SHRSP_Female,
SHR_Both, SHR_Male, GH_Both, GH_Male
LEW_Both, LEW_Male, LEW_Female

1+2+3

1+4

1+4+5

1+2+3+
4+5

2/5

2/4

2/4

3/4

3/1(optimal) or
4/2

3.5
3
2.5
2

Distinguish Ability

1.5

Number of Clusters

1
0.5
0
2 Features

3 Features

5 Features

Figure 45 Distinguish Power and Number of Clusters for Different Models

3.2

Results and Conclusion

The Model (1+2+3+4+5) proved to be the best model and the optimal number of clusters k
was 3 after merging “SHR_Female” into cluster “SHRSP_Both, SHRSP_Male, SHRSP_Female,
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SHR_Both, SHR_Male, GH_Both, GH_Male”. K=3 was optimal because if we kept the
“SHR_Female” cluster and moved “SHR_Both, SHR_Male” into the small cluster, there were
2 wrong assignments and the “Distinguish Power” was reduced.

Figure 46 Scatter Plot for Model (1+2+3+4+5) with Different Features as XY Axis (Three Clusters)

Figure 46 shows the scatter plot for Model (1+2+3+4+5) with different features for the XY
axes. There are three clusters in the graph. We can see that the dark blue and light blue
clusters are actually very close to each other in the two dimensional scatter plot. However,
we were able to successfully distinguish the two clusters “WKY_Both, WKY_Male,
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WKY_Female, BN_Both, BN_Male” and “LEW_Both, LEW_Male, LEW_Female” using five
features.
We then included data from mutant strains and outbred strains into our analysis. We found
that mutant strains and outbred strains only include Features 3, 4 and 5 (systolic blood
pressure, heart rate, and heart wet weight). We were only able to identify two significant
clusters (a small cluster with only one item was merged into the first cluster) (Table 4).
Figure 47 shows the scatter plot for Model (3+4+5) with different features on the XY axes.
There are three clusters in the graph but we merged one cluster with only one item into the
dark blue cluster (first cluster in Table 4).
Table 4 Clustering Results for Inbred, Outbred and Mutant Strains under Naïve Control Condition
Model

3+4+5

Cluster
ACI-Lystbg-Kyo/Kyo, BN/KunKtsSlc, BN_Both, BN_Male, Crl:SD, Crl:WI, DMY/Kyo, DMYC/Kyo,
F344. Cg-Du TyrCKyo+/+, F344. CVD-Unc5ccvd/Kyo, F344_Both, F344_Female, F344_Male,
F344-Apcm1Kyo, F344-Egrm1Kyo, F344-HrKrh/Kyo, F344-Kmch/Kyo, F344-Kuru2/Kyo, F344Scn1am1Kyo, F344-Scn1am2Kyo, F344-Sv2am1Kyo, F344-Tbr1/Kyo, F344-Trdk/Kyo,
FH/HamSlc, Gunn-Ugt1a1jSlc, HOB/Snk, HOB-Unc5chob/Snk, HTX/Kyo, HWY/Slc, KCI/Kyo,
KFRS2/Kyo, KFRS2/Kyo-/+, KFRS3A/Kyo, KFRS3A/Kyo+/+, KFRS3B/Kyo, KFRS4/Kyo, KFRS6/Kyo,
KHR/Kyo, KHR/Kyo-/-, KHR/Kyo-/+, KZ-LeprfaTky, LE_Both, LE_Male, LEC/Hok, LEW_Both,
LEW_Female, LEW_Male, NAR/Slc, SER/Kyo, SHR_Female, SS_Both, SS_Male, TRM/Kyo,
WKY_Both, WKY_Female, WKY_Male, WTC-swh/Kyo
GH_Both, GH_Male, SHR_Both, SHR_Male, SHRSP/Ta, SHRSP_Both, SHRSP_Female,
SHRSP_Male, WTC-Kcnq1dfkKyo, ZI/Kyo
OP/Jtt
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Figure 47 Scatter Plot for Model (3+4+5) with Different Features as XY Axis

The result agrees with the general classification or normal (control) and abnormal
(hypertensive) strains but the ability to further classify normal strains into sub-clusters is
lower than the full model with five features. This result indicates that more data for outbred
and mutant strains on diastolic blood pressure and mean arterial blood pressure will be
needed to further cluster strains into sub-populations.
As previously noted, researchers have often been constrained by availability of particular
strains and familiarity or previous studies using those strains. Statistically clustering rat
strains based on phenotypic profiles, such as what was done with the multiple
cardiovascular phenotypes provides researchers with another tool to 1) identify the
subpopulation of strains similar to the one in use to analyze data from these similar strains,
2) examine if they could use an alternative strain that is more readily available to them to
substitute for those used by other researchers (given their closeness in the cluster); 3)
examine any sex or age specific differences that might position some strains on the border
of being “normal” or “abnormal” and thus not ideal to be used as a control strain.
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4 Conclusions, Discussion and Future Directions
This project resulted in a platform consisting of 1) an analysis pipeline with user interface to
generate expected ranges for phenotypes, and 2) a web-based data mining and visualization
tools to provide easy access to this data for researchers. The pipeline and interface provides
the means to 1) identify expected ranges for many types of quantitative phenotypes for
different strains and different experimental conditions, 2) identify phenotypes without
sufficient data to determine an expected range to prioritize these for acquisition through
direct contact with researchers or extraction from published literature, 3) alert RGD staff of
new phenotype data in PhenoMiner and potential changes in expected range so the pipeline
can be run to determine expected ranges with this new additional data.
The data mining and visualization tools created in this project provide the ability to 1) query
by phenotype or strain to retrieve expected ranges, 2) generate a profile of multiple
phenotypes for a single strain, 3) compare expected ranges for phenotypes across strains,
sexes and ages, 4) compare expected ranges for particular phenotypes and strains with the
expected range for control animals. Such resources will allow researchers with information
necessary to design studies and choose appropriate strains for their needs. A pilot cluster
analysis using the expected ranges for multiple phenotypes demonstrated that such data
can be used to group strains with similar phenotype profiles, providing additional resources
for researchers interested in comparisons among similar strains or to assist in choosing
strains with similar profiles.
Based on the success of this project, the Rat Genome Database will develop a Precision
Models Portal to present these data and link to others to provide a rich resource for
investigators. The results of this study will be used to target phenotype areas for data
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acquisition and analysis. The goal will be to provide comprehensive profiles based on the
expected ranges for phenotypes across all major physiological systems. The availability of
sequence and variant data for a number of the strains will offer the opportunity to provide a
complementary genotype profile with the phenotype profile to enhance the ability of
researchers to choose models based on both genotype and phenotype. Continued cluster
analysis of the strains across multiple phenotype areas and as data expands, will provide
additional information for researchers. Expanding the analysis method into a tool will also
allow researchers to customize the profile of phenotypes for which they want to classify
strains. Expansion of data mining and visualization tools could include allowing users to 1)
upload their own data for comparison, 2) choose more than one phenotype to compare
across strains in a single view, 3) integrate genotype in a visual manner.
Animal models used to study human diseases are developed to exhibit phenotypes similar
to those of humans suffering from a particular disease (90-92). Researchers have a long
history of developing such models, particularly in rat, and quantitatively measuring
phenotypes of interest and statistically analyzing these against those measured in control
animals. However, there has not been a comprehensive effort to statistically analyze
quantitative phenotype measurements across multiple experiments to establish expected
ranges for disease model rat strains and controls. The methods and statistical algorithms
established in this project provide the platform for identifying and validating expected
ranges for a variety of quantitative phenotypes. The development of interfaces and
automation of the pipeline provide the ability to continuously add new expected ranges for
particular phenotypes or strains and update existing ranges as new data becomes available.
This data resource and the data mining and visualization tools will promote understanding
of rat disease models, guide researchers to choose optimal strains for their research needs,
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and encourage data sharing from different research hubs. Such resources help to promote
research reproducibility. The value of the methods, platforms and data produced here go
beyond the rat research community. The analysis pipeline can easily be adapted for multiple
types of studies involving quantitative clinical or experimental results. Such methods have
already been used to some extent with clinical trials but could be adapted for electronic
phenotype analyses using data from Electronic Medical Records. The creation of a Precision
Model Portal as an outgrowth of this project will provide a valuable resource for the
Precision Medicine research efforts. It will increase the ability of those identifying variants
that potentially impact a phenotype or set of phenotypes in a patient or human population
to be able to identify the appropriate rat strain that mimics both the phenotype profile and
genotype profile of that patient or population. Expanding on the analysis pipelines, data
produced and interactive platforms created in this project will continue to provide a
valuable resource for Translational Research.
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APPENDIX A: META-ANALYSIS SUMMARIES FOR 24
CARDIOVASCULAR PHENOTYPES
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APPENDIX B: SUMMARY OF ABNORMAL AND NORMAL STRAINS
FOR 24 CARDIOVASCULAR PHENOTYPES
Phenotype

Abnormal

Normal

blood hemoglobin level

Naïve
Control

all

diastolic blood pressure

GH, LH, SHR,
SHRSP

BN, HTG, LEW, MHS, WKY

BN, WKY

heart left ventricle weight to
body weight ratio

SHR

COP, DA, DRY, F344, LEW, WKY

WKY

heart left ventricle wet weight

GH

BN, COP, DA, DRY, F344, LEW,
SHR, WKY

BN, WKY

heart rate

ACI, DA, GK

BN, WKY

heart right ventricle weight to left
ventricle weight ratio

F344, FHH, GH

BN, BUF, F344, FHH, GH, LE,
LEW,
SHR, SHRSP, SS, WAG, WKY
LE, LEW, SHR, SS, WKY
F344, WKY

WKY

ACI, BN, BUF, COP, DA, F344,
GK, LE,
LEW, SS, WAG, WKY
ACI, BN, BUF, COP, DA, F344,
ISIAH, M520, MWF, SHR, WAG,
WKY, WN
ACI, BN, COP, DA, F344, LE, LEW,
MWK, WAG, WKY

BN, WKY

heart right ventricle wet weight
heart weight as percentage of
body weight

FHH, SHR,
SHRSP

heart weight to body weight ratio

SHRSP

heart wet weight

BUF, FHH, GH,
SS

hematocrit
mean arterial blood pressure

WKY

BN, WKY

BN, WKY

all
GH, SHR,
SHRSP

BN, LE, LEW, SS, WKY

mean corpuscular volume

all

plasma total cholesterol level

HTG, LEW

plasma triglyceride level

COP, HTG, LEW

red blood cell count

all

BN, WKY

serum aspartate
aminotransferase activity level

SHR

BN, F344, FHH, GH, LE, LEW, SS,
WKY

BN, WKY

serum calcium level

F344, GH, LE

BN, FHH, LEW, SHR, SS, WKY

BN, WKY
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serum chloride level

all

serum free fatty acids level

F344

serum potassium level

all

serum total cholesterol level

GH, MWF,
SHRSP

serum triglyceride level

DA, WOKW

systolic blood pressure

GH, LH, MHS,
SHR, SHRSP
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BN, DA, EHC, F344, FHH, GH,
LEW,
SHR, SS, WKY, WOKW
BN, EHC, F344, MWF, SHR

BN, WKY

ACI, BN, BUF, DA, F344, GK, LE,
LEW,
LN, M520, MNS, MR, MWF, WKY

BN, WKY

BN

APPENDIX C: AGREEMENTS BETWEEN META-ANALYSIS RESULTS
AND DOMAIN EXPERT EMPIRICAL KNOWLEDGE
Phenotype

Agreement

Disagreement

blood hemoglobin level

31

0

diastolic blood pressure

23

0

heart left ventricle weight to body weight ratio

13

0

heart left ventricle wet weight

15

2

heart rate

41

1

heart right ventricle weight to left ventricle weight ratio

24

3

heart right ventricle wet weight

2

0

heart weight as percentage of body weight

36

3

heart weight to body weight ratio

20

0

heart wet weight

44

1

hematocrit

33

0

mean arterial blood pressure

30

0

mean corpuscular volume

31

0

plasma total cholesterol level

5

0

plasma triglyceride level

7

0

red blood cell count

27

0

serum aspartate aminotransferase activity level

27

0

serum calcium level

27

0

serum chloride level

27

0

serum free fatty acids level

2

0

serum potassium level

27

0

serum total cholesterol level

35

0

serum triglyceride level

12

0

systolic blood pressure

27

1
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